Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Accumulated Depreciation & Amortization Accumulated Depreciation & Amortization Cost of Revenue Depreciation & Amortization (IS)Gross Profit Leases Long-Term Debt Issuances Machine, Furnitures, Fixtures & Other Other Gross PP&E Adjustments Other Gross PP&E Adjustments Property, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - Net Receivables - Other Shares Issued Shares Outstanding Shares Outstanding

Ocular Therapeutix (OCUL) Long-Term Debt Repayments (2017 - 2021)

Ocular Therapeutix has reported Long-Term Debt Repayments over the past 5 years, most recently at $2.1 million for Q2 2021.

For Q2 2021, Long-Term Debt Repayments changed N/A year-over-year to $2.1 million; the TTM value through Dec 2023 reached $2.1 million, changed N/A, while the annual FY2023 figure was $26.1 million, N/A changed from the prior year.
Long-Term Debt Repayments for Q2 2021 was $2.1 million at Ocular Therapeutix, roughly flat from $2.1 million in the prior quarter.
Over five years, Long-Term Debt Repayments peaked at $2.1 million in Q2 2021 and troughed at $1.0 million in Q1 2018.
A 3-year average of $1.6 million and a median of $1.5 million in 2018 define the central range for Long-Term Debt Repayments.
On a YoY basis, Long-Term Debt Repayments climbed as much as 20.85% in 2018 and fell as far as 20.85% in 2018.
Year by year, Long-Term Debt Repayments stood at $1.3 million in 2017, then grew by 18.69% to $1.5 million in 2018, then skyrocketed by 35.06% to $2.1 million in 2021.
Business Quant data shows Long-Term Debt Repayments for OCUL at $2.1 million in Q2 2021, $2.1 million in Q1 2021, and $1.5 million in Q4 2018.